BusinessVoyager Therapeutics and CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntington’s DiseaseBy Nasdaq OMXSep 12, 2016, 11:05 AM UTC
BusinessBioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy ProgramBy Nasdaq OMXApr 20, 2016, 12:30 PM UTC
BusinessBioMarin Receives European Orphan Drug Designation for BMN 270, First Investigational AAV-Factor VIII Gene Therapy for Patients with Hemophilia ABy Nasdaq OMXMar 24, 2016, 12:30 PM UTC
BusinessBioMarin Receives Orphan Drug Designation From FDA for First AAV-Factor VIII Gene Therapy, BMN 270, for Patients With Hemophilia ABy Nasdaq OMXMar 1, 2016, 10:43 PM UTC
BusinessGenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic NeuropathyBy Nasdaq OMXFeb 29, 2016, 12:00 PM UTC
BusinessAGTC Announces Data Evaluating Novel AAV-Based Gene Therapy as a Potential Treatment for Alpha-1 Antitrypsin (AAT) DeficiencyBy Nasdaq OMXJan 20, 2016, 12:01 PM UTC
BusinessAGTC Announces Preclinical Data Evaluating Cone-Specific Promoters for Use in Gene Therapy of Achromatopsia and Other Retinal DiseasesBy Nasdaq OMXJan 7, 2016, 12:01 PM UTC
